Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, single-arm, open-label, phase II trial for the frontline treatment of
relapsed AML or MDS following allo-HCT. Eligible subjects will receive up to 4 cycles of
combined modality treatment. The number of cycles depends on response, toxicity, and the
remaining cell dose.